Investors who owned stocks in the 2010s generally experienced some big gains. In fact, the SPDR S&P 500 SPY total return for the decade was 250.5%. But there’s no question some big-name stocks did much better than others along the way.
Novavax’s Difficult Decade: One poor performer of the last decade was biotech stock Novavax, Inc. NVAX.
Novavax spent much of the past decade under the radar, but its potential role in developing a vaccine for the COVID-19 coronavirus has gotten Wall Street’s attention in 2020.
Prior to 2020, Novavax’s first big run on Wall Street came in 2015 when the company received an $89 million grant from the Bill & Melinda Gates Foundation to develop a vaccine for human respiratory syncytial virus, or RSV. The stock skyrocketed in 2015 after the company reported encouraging Phase 2 trial data for its RSV vaccine candidate ResVax, but it crashed more than 85% in 2016 after ResVax failed in Phase 3 trials.
COVID-19 Impact: When the COVID-19 outbreak started getting serious in 2020, Novavax was one of the first biotech companies to begin testing a COVID-19 vaccine, NVX-CoV2373. In May, Novavax received $384 million in funding from the Coalition for Epidemic Preparedness Innovations to help fund the development and testing of NVX-CoV2373.
Just this week, the New England Journal of Medicine published a study demonstrating Novavax’s COVID-19 vaccine candidate has been both safe and effective in eliciting an immune response in patients. However, Novavax is one of more than 70 companies currently working on a COVID-19 vaccine, and there’s certainly no guarantee Novavax’s product will be the first or best one on the market.
Related Link: Here's How Much Investing $1,000 In Inovio Stock Back In 2010 Would Be Worth Today
Novavax started the 2010s trading at around $2.80. By mid-2011, the stock had traded down to under $1.20 before optimism started to build surrounding ResVax. By mid-2015, the ResVax buying frenzy had reached its peak, and the stock topped out at $15.01. Following the Phase 3 failure, Novavax shares crashed back below $2 in late 2016.
When the company announced a 20-to-1 reverse stock split in early 2019, Novavax hit its decade low of 34 cents.
2020 And Beyond: COVID-19 speculation has driven Novavax shares as high as $189.40 so far in 2020, but the stock still hasn’t regained its split-adjusted decade highs from back in 2015.
The COVID-19 rally has made Novavax shares a profitable investment over the past decade, but the return isn’t particularly outstanding. In fact, $1,000 worth of Novavax stock in 2010 would be worth about $2,403 today.
Looking ahead, analysts are optimistic the COVID-19 rally will continue. The average price target among the five analysts covering the stock is $257, suggesting about 130.5% upside from current levels.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.